TD-6450
- Generic Name
- TD-6450
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
Phase 2
Completed
- Conditions
- Chronic Hepatitis CHepatitis C (HCV)Hepatitis C Genotype 1Hepatitis C Viral Infection
- Interventions
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- Trek Therapeutics, PBC
- Target Recruit Count
- 25
- Registration Number
- NCT02716428
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸Bach and Godofsky Infectious Diseases, Bradenton, Florida, United States
🇳🇿Auckland Clinical Studies, Auckland, New Zealand
A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
Phase 2
Completed
- Conditions
- Hepatitis C Viral InfectionChronic Hepatitis CHepatitis C Genotype 4Hepatitis C (HCV)
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Trek Therapeutics, PBC
- Target Recruit Count
- 16
- Registration Number
- NCT02593162
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
TD-6450 MAD Study in HCV Infected Subjects
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 47
- Registration Number
- NCT02116543
- Locations
- 🇺🇸
Texas Liver Institute, San Antonio, Texas, United States
TD-6450 SAD and MAD in Healthy Subjects
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 111
- Registration Number
- NCT02022306
- Locations
- 🇺🇸
ICON Development Solutions, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath